Bedrock Healthcare Communications is proud to accept the PMEA for Agility in Pharma Market Excellence

During the COVID-19 pandemic, multiple sclerosis (MS) experts were receiving many questions regarding the safety and efficacy of COVID-19 vaccination in patients receiving treatment for MS. The challenge was developing robust guidance in a timely manner with a goal of providing clarity on vaccine timing, efficacy, and safety, to support healthcare professionals and their patients.

An international Steering Committee of 10 MS experts came together to discuss, refine, and finalise 13 clinical recommendations. A further 28 MS experts from 19 countries also voted on the recommendations and helped to reach robust consensus through a virtual voting platform within a 90-day timeframe.

“Merck KGaA and Bedrock identified a beautifully simple solution to a pressing need. The judges recognised that achieving actional consensus on guidelines is always challenging, which is exacerbated by HCPs’ workloads, but the results achieved here are impressive. The approach was bold and imaginative, and the execution very well planned and delivered” PMEA Judging Panel 2022.

Stephen Marchant, MD of Bedrock said “We would like to add congratulations to Hashem Salloukh for partnering and trusting us with this critical project that provided a clear patient benefit. I would also like to thank my Bedrock team. This award is a testament to their freethinking, agility, and our belief that no two business challenges are the same.”

If you are looking for a team of freethinkers with bold and imaginative approaches to medical communications get in touch  freethinking@bedrock-health.com